Want to see FR:AB full AI Analyst Report?
Top Page
AB Science SA
(AB)
Select Model
Select Model
Rating:41Neutral
Price Target:
€0.50
▼(-32.43% Downside)
Action:Reiterated
Date:09/30/26
The score is driven primarily by weak financial performance (persistent losses, negative equity, and renewed free-cash-flow burn), which elevates financing and solvency risk. Technicals add pressure with a clear downtrend across key moving averages, only partially offset by oversold readings. Valuation provides limited support because the company is loss-making (negative P/E) and offers no stated dividend yield.
Positive Factors
Revenue Growth
Improving revenue growth indicates that AB Science is generating increasing commercial or development-related inflows despite its small scale. If this trend continues, a larger revenue base could gradually improve operating leverage and provide greater support for advancing its pipeline.
Negative Factors
Persistent Unprofitability
Continued operating and net losses show that the business has not yet reached an economically sustainable scale. Persistent unprofitability can consume capital needed for clinical development and makes future earnings dependent on successful approvals, commercialization, or additional funding.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Improving revenue growth indicates that AB Science is generating increasing commercial or development-related inflows despite its small scale. If this trend continues, a larger revenue base could gradually improve operating leverage and provide greater support for advancing its pipeline.
Read all positive factors
AB Science SA (AB) vs. iShares MSCI France ETF (EWQ)
Market Cap
€53.00M
Dividend YieldN/A
Average Volume (3M)215.49K
Price to Earnings (P/E)―
Beta (1Y)1.45
Revenue Growth12.66%
EPS Growth44.01%
CountryFR
Employees31
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.08
Shares Outstanding96,530,785
10 Day Avg. Volume323,236
30 Day Avg. Volume215,491
Financial Highlights & Ratios
PEG Ratio0.73
Price to Book (P/B)-5.48
Price to Sales (P/S)80.33
P/FCF Ratio-20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)€1.20M
AB Science SA Business Overview & Revenue Model
Company Description
AB Science S.A. is a pharmaceutical company dedicated to the discovery, development, and commercialization of protein kinase inhibitors for applications in both human and animal health. Its primary drug candidate, masitinib, a tyrosine kinase inhi...
How the Company Makes Money
AB Science’s business model is centered on developing proprietary drug candidates and monetizing them through (i) commercial sales if/when products obtain marketing authorization and are launched, and/or (ii) partnering transactions (e.g., out-lic...
AB Science SA Financial Statement Overview
Summary
Income Statement
26
Negative
Balance Sheet
22
Negative
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.16M | 1.17M | 1.07M | 970.00K | 958.00K | 1.61M |
| Gross Profit | 361.00K | 720.00K | 1.25M | 587.00K | 927.00K | 1.50M |
| EBITDA | -9.01M | -1.22M | -4.92M | -11.16M | -13.41M | -17.36M |
| Net Income | -5.41M | -1.56M | -7.83M | -10.05M | -13.62M | -14.46M |
Balance Sheet | ||||||
| Total Assets | 18.09M | 24.52M | 23.18M | 25.50M | 23.84M | 21.27M |
| Cash, Cash Equivalents and Short-Term Investments | 8.98M | 10.18M | 7.99M | 6.07M | 7.27M | 8.72M |
| Total Debt | 4.74M | 4.24M | 18.47M | 19.10M | 23.96M | 8.35M |
| Total Liabilities | 35.15M | 34.34M | 46.93M | 46.51M | 59.51M | 44.47M |
| Stockholders Equity | -22.45M | -17.20M | -23.75M | -21.01M | -35.67M | -23.20M |
Cash Flow | ||||||
| Free Cash Flow | -4.74M | -4.57M | 370.00K | -17.22M | -18.11M | -17.74M |
| Operating Cash Flow | -4.54M | -4.29M | 525.00K | -16.87M | -17.47M | -17.18M |
| Investing Cash Flow | -121.00K | -224.00K | -136.00K | -614.00K | -360.00K | -590.00K |
| Financing Cash Flow | 8.61M | 6.69M | 1.53M | 16.27M | 16.39M | 5.84M |
AB Science SA Technical Analysis
Negative
0.74
Price Trends
0.69
Negative
0.73
Negative
0.99
Negative
Market Momentum
-0.05
Positive
34.07
Neutral
17.95
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:AB, the sentiment is Negative. The current price of 0.74 is above the 20-day moving average (MA) of 0.63, above the 50-day MA of 0.69, and below the 200-day MA of 0.99, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 34.07 is Neutral, neither overbought nor oversold. The STOCH value of 17.95 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:AB.
AB Science SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | €85.89B | 21.90 | 5.52% | 11.64% | 15.30% | -35.58% | |
65 Neutral | €11.92B | 23.24 | 11.33% | 1.11% | 13.63% | 14.45% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | €143.20M | -2.51 | 152.56% | ― | -29.48% | 7.91% | |
41 Neutral | €53.00M | -6.82 | 27.28% | ― | 12.66% | 44.01% | |
41 Neutral | €50.07M | -1.26 | -96.73% | ― | -96.25% | -197.89% | |
41 Neutral | €82.38M | -1.94 | -94.14% | ― | -5.98% | -8.67% |
* Healthcare Sector Average
FR:AB
AB Science SA
0.55
-0.75
-57.77%
FR:IPH
Innate Pharma SA
1.28
-0.40
-23.69%
FR:IPN
Ipsen
144.10
30.31
26.64%
FR:OSE
OSE Immunotherapeutics SA
2.13
-4.55
-68.14%
FR:SAN
Sanofi
71.60
-8.10
-10.17%
FR:ALCLS
Cellectis SA
1.14
-2.76
-70.79%
AB Science SA Corporate Events
AB Science Overhauls Strategy as Loss Widens but Financing and Trials Advance
Oct 9, 2026
AB Science has launched a major governance overhaul with the appointment of Stéphane Ledermann as chairman and chief executive, marking a strategic relaunch aimed at extracting more value from its pipeline and assets. The new plan prioritises...
AB Science Resets Clinical Timelines After GCP Inspection and Strengthens Quality Strategy
Sep 29, 2026
AB Science has revised its development plan and financial calendar after a multi-country Good Clinical Practice inspection of its sponsored trials, reinforcing new management’s decision to prioritize a strengthened quality management system ...
AB Science Completes €14.2 Million Private Placement, Bolstering Funding for Drug Pipeline
Aug 17, 2026
AB Science has completed the settlement and delivery of securities issued under a €14.2 million private placement subscribed by a limited number of investors, involving new ordinary shares with attached share subscription warrants that could...
AB Science Raises €14.2 Million to Drive R&D and Strategic Transformation
Aug 10, 2026
AB Science has completed a €14.2 million private placement, largely subscribed by an existing long-term investor, bringing its cash position to around €23 million and covering working capital needs beyond the next 12 months. The CEO al...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.